Source: HOSPEEM. Brussels, 24/09/2020 Every year more than 12.7 million healthcare workers in Europe, including 7.3 million nurses, are potentially exposed to carcinogenic, mutagenic and reprotoxic hazardous drugs. Studies show that hospital workers who handle cytotoxic drugs are three… Read more
News
Position Statement on Rapid Antigen Point of Care Tests for COVID and Influenza
A number of new diagnostic tests for SARS CoV2 are being and will be launched in the coming weeks with rapid point of care antigen tests being the most important technological innovation. Some months ago, the US Federal Drug Administration… Read more
COVID and Influenza Preparedness in Europe
The COVID-19 pandemic and its repercussions will continue for some time and is likely to continue to place an ongoing burden on already stretched healthcare workers and patients in Europe, which will be exacerbated if it coincides with the seasonal… Read more
COVID-19 Vaccination Programme
COVID-19 vaccination is the most important global healthcare initiative at the moment and by the end of 2020/beginning of 2021, it is expected that pharmaceutical companies will start to deliver the first vaccines in Europe but probably not enough for… Read more
EBN feedback to Europe’s Beating Cancer Plan
Preventing exposure to carcinogenic hazardous drugs Europe’s Beating Cancer Plan for Europe has to consider the potential benefits for workers, the healthcare system, patients and their families, by what has already identified as a preventive instrument in the roadmap, namely… Read more
Summary of European Biosafety Network Lisbon Summit
On 5 December 2019 the European Biosafety Network hosted a Summit at Infarmed in Lisbon to explore the issue of preventing the exposure of healthcare workers to hazardous drugs. Luca Scarpiello of EPSU said there is a greater need… Read more
Summary of European Biosafety Network Rome Summit
On 29 October 2019 the European Biosafety Network held a Summit at the Italian Ministry of Health in Rome to discuss the exposure of healthcare workers to hazardous drugs. The Summit was split into three sessions including a keynote… Read more
2019 European Biosafety Network Summit in Rome
Registration opens for European Biosafety Network Summit in Rome Registration has opened for the next European Biosafety Summit, taking place on 29 October 2019 at the Italian Ministry of Health in Rome. All attendees must register ahead of the Summit… Read more
EBN publishes brochure in 8 languages on latest amendments to Carcinogens and Mutagens Directive and their implications for the healthcare sector
The brochure, titled Amendments to the Carcinogens and Mutagens Directive on hazardous drugs and implications for change to the healthcare system in Europe to ensure compliance with its requirements, was initially published in English, but has now been translated into… Read more
Amendments to the Carcinogens and Mutagens Directive on hazardous drugs and implications for change to the healthcare system in Europe to ensure compliance with its requirements
Click below to download amendments and implications Amendments and Implications of CMD3 – English The European Parliament unanimously approved amendments to Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens… Read more
